MedPacto, Inc.
Oncology drug developer spun off from Theragen Etex, advancing TGF-β inhibitor Vactosertib as its lead pipeline candidate.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSpun off from Theragen Etex's drug discovery institute, MedPacto was founded in 2013 and listed on KOSDAQ in 2019 as an oncology drug development company. Its lead pipeline is the TGF-β inhibitor Vactosertib, alongside follow-on candidates MP010, a tumor-microenvironment-targeting fusion protein, and MP2021 for bone and autoimmune diseases. Vactosertib is in Phase 1/2 as monotherapy for osteosarcoma and Phase 2b/3 in combination with pembrolizumab for colorectal cancer in the US and Korea, under co-development agreements with AstraZeneca's Imfinzi and MSD's Keytruda.
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2018–2023 (Phase 1 2 · Phase 2 2 · Phase 1/2a 2 · Phase 1/2 1)
- Phase 1/2백토서팁(TEW-7197)2023-02-15
6 trial sites
- Phase 1백토서팁(TEW-7197)2023-02-14
2 trial sites
- Phase 2백토서팁(TEW-7197)2021-11-23
6 trial sites
- Phase 2백토서팁(TEW-7197)2020-08-06
10 trial sites
- Phase 1/2a백토서팁(TEW-7197)2018-10-01
4 trial sites
- Phase 1/2a백토서팁(TEW-7197)2018-09-07
5 trial sites
- Phase 1백토서팁(TEW-7197)2018-06-18
1 trial site
R&D and key agreements
Source: DART corporate disclosure백토서팁 (Vactosertib) · 골육종 · 1/2상 · Monotherapy, US and Korea
백토서팁 (Vactosertib) · 대장암 · 2b/3상 · Combination with pembrolizumab (Keytruda), US and Korea
MP010 · 난치성 고형암 · 전임상 · Recombinant fusion protein targeting tumor microenvironment
MP2021 · 골다공증, 류마티스관절염, 뼈 전이 · 전임상 · Targets TM4SF19
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer4
- OpenAIOAI-SearchBot2
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 27, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition